Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Receivables for 7 consecutive years, with $42.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 1564.73% to $42.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.6 million, a 1564.73% increase, with the full-year FY2025 number at $42.6 million, up 1564.73% from a year prior.
  • Receivables was $42.6 million for Q4 2025 at ImmunityBio, up from $33.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $42.6 million in Q4 2025 to a low of $700000.0 in Q1 2024.
  • A 4-year average of $11.2 million and a median of $2.9 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: dropped 21.52% in 2024, then skyrocketed 2342.14% in 2025.
  • ImmunityBio's Receivables stood at $1.3 million in 2022, then soared by 55.31% to $2.0 million in 2023, then grew by 26.8% to $2.6 million in 2024, then surged by 1564.73% to $42.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Receivables are $42.6 million (Q4 2025), $33.7 million (Q3 2025), and $22.2 million (Q2 2025).